[go: up one dir, main page]

BR9814319A - Aplicação de pró-drogas de enzima como agentes antinfecciosos - Google Patents

Aplicação de pró-drogas de enzima como agentes antinfecciosos

Info

Publication number
BR9814319A
BR9814319A BR9814319-0A BR9814319A BR9814319A BR 9814319 A BR9814319 A BR 9814319A BR 9814319 A BR9814319 A BR 9814319A BR 9814319 A BR9814319 A BR 9814319A
Authority
BR
Brazil
Prior art keywords
application
provides
enzyme
prodrugs
infectious agents
Prior art date
Application number
BR9814319-0A
Other languages
English (en)
Inventor
H Michael Shepard
Original Assignee
Newbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiotics Inc filed Critical Newbiotics Inc
Publication of BR9814319A publication Critical patent/BR9814319A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Patente de Invenção: <B>"APLICAçãO DE PRó-DROGAS DE ENZIMA COMO AGENTES ANTIINFECCIOSOS"<D>. A presente invenção provê um método para o direcionamento de antimetabolitos tóxicos para as infecções gram-negativas. Ela provê um meio de tirar vantagem de um mecanismo de resistência à doença chave para ativar estas drogas localmente, e para superar o fenótipo de resistência dos micróbios. A invenção ulteriormente provê um método para a seleção quanto à sensibilidade de antibiótico, uma vez que um mecanismo provável pelo qual organismos provavelmente ganham resistência às pró-drogas é via perda de atividade de enzima que produzirá bactérias sensíveis a antibióticos mais uma vez.
BR9814319-0A 1997-12-23 1998-12-22 Aplicação de pró-drogas de enzima como agentes antinfecciosos BR9814319A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6870397P 1997-12-23 1997-12-23
PCT/US1998/027493 WO1999032113A1 (en) 1997-12-23 1998-12-22 Application of enzyme prodrugs as anti-infective agents

Publications (1)

Publication Number Publication Date
BR9814319A true BR9814319A (pt) 2000-10-10

Family

ID=22084202

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814319-0A BR9814319A (pt) 1997-12-23 1998-12-22 Aplicação de pró-drogas de enzima como agentes antinfecciosos

Country Status (10)

Country Link
US (1) US6159706A (pt)
EP (1) EP1041983A4 (pt)
JP (1) JP2001526060A (pt)
CN (1) CN1285745A (pt)
AU (1) AU759639B2 (pt)
BR (1) BR9814319A (pt)
CA (1) CA2315201A1 (pt)
IL (1) IL136925A0 (pt)
MX (1) MXPA00006109A (pt)
WO (1) WO1999032113A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
WO2001083492A1 (en) * 2000-05-02 2001-11-08 Newbiotics, Inc. Improved beta-lactam antibiotics
DE10029185A1 (de) * 2000-06-19 2002-01-03 Henkel Kgaa Verfahren zur antimikrobiellen Behandlung von durch mikrobiellen Befallgefährdeten Materialien
JP4109123B2 (ja) * 2001-05-09 2008-07-02 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド ペプチドデホルミラーゼ活性化プロドラッグ
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
CA2482029A1 (en) * 2002-04-18 2003-10-30 Maria V. Sergeeva Peptide deformylase activated prodrugs
CA2505914A1 (en) * 2002-11-14 2004-05-27 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1348984A (en) * 1970-06-16 1974-03-27 Merck & Co Inc Antibiotics and processes for their production
DK151027C (da) * 1974-08-09 1988-03-07 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af 7alfa-methoxy-7beta-(2-aminothiazol-4-ylacetamido)cephalosporiner eller farmaceutisk acceptable salte eller estere deraf
FR2550200B1 (fr) * 1983-08-01 1988-04-08 Fujisawa Pharmaceutical Co Procede de preparation de composes de cephem a activite antimicrobienne et nouveaux produits ainsi obtenus
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA886812B (en) * 1987-11-23 1989-07-26 Bristol Myers Co Anti-tumor prodrugs
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5525599A (en) * 1993-07-21 1996-06-11 Eli Lilly And Company 7-substituted-amino-3-substituted-3-cephem-4-carboxylic acids
WO1995026966A1 (en) * 1994-04-01 1995-10-12 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics
US5679773A (en) * 1995-01-17 1997-10-21 Affymax Technologies N.V Reagants and methods for immobilized polymer synthesis and display
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
JPH08325270A (ja) * 1995-05-31 1996-12-10 Bristol Myers Squibb Co β−ラクタマーゼに対するポリマープロドラッグおよびその使用
MY127641A (en) * 1995-10-12 2006-12-29 Essential Therapeutics Inc Cephalosporin antibiotics

Also Published As

Publication number Publication date
IL136925A0 (en) 2001-06-14
CN1285745A (zh) 2001-02-28
EP1041983A4 (en) 2002-09-11
US6159706A (en) 2000-12-12
AU759639B2 (en) 2003-04-17
WO1999032113A1 (en) 1999-07-01
JP2001526060A (ja) 2001-12-18
CA2315201A1 (en) 1999-07-01
MXPA00006109A (es) 2002-07-09
EP1041983A1 (en) 2000-10-11
AU2094099A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
Kim et al. Terrein is an inhibitor of quorum sensing and c-di-GMP in Pseudomonas aeruginosa: a connection between quorum sensing and c-di-GMP
Descourouez et al. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents
BR9814319A (pt) Aplicação de pró-drogas de enzima como agentes antinfecciosos
Calfee et al. Interference with Pseudomonas quinolone signal synthesis inhibits virulence factor expression by Pseudomonas aeruginosa
Totsika Disarming pathogens: benefits and challenges of antimicrobials that target bacterial virulence instead of growth and viability
Berghoff et al. RNA-based regulation in type I toxin–antitoxin systems and its implication for bacterial persistence
BR9913225A (pt) Novos agentes antibacterianos de isoxazolinona
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
CY1107181T1 (el) Συνδυασμος ζιζανιοκτονων με ακυλιωμενες αμινοφαινυλοσουλφονυλουριες
BR0009314A (pt) Uso de um composto como fungicida, compostos fungicidas, composição fungicida e método de combate a fungos
BRPI0516463A (pt) cánula escalonada e conjunto de cánula
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
BR0312217A (pt) Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
PT1077718E (pt) Melhoramentos da actividade de agentes antibacterianos de oxazolidinona por derivados de arginina
PT920421E (pt) Derivados de isoxazolina uteis como agentes antimicrobianos
BR9609281A (pt) Método para o controle de bactérias gram-positivas resistentes a antibióticos e tratamento de infecções
BR0112350A (pt) Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
ATE347356T1 (de) Hydroxamsäurederivate als antibakterielle arzneimittel
Turos et al. N-Thiolated β-lactams: A new family of anti-Bacillus agents
Fraser-Pitt et al. Cysteamine inhibits glycine utilisation and disrupts virulence in Pseudomonas aeruginosa
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
ATE343386T1 (de) Sgk3 als diagnostisches und therapeutisches target
WO2005000195A3 (en) A pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger
BR7902303Y1 (pt) tambor para tratamento de couros, peles e similares.
ATE213624T1 (de) Marker für eine darm-diagnostik und darm-therapie

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.